FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W110747544> ?p ?o ?g. }

• W110747544 endingPage "91" @default.
• W110747544 startingPage "91" @default.
• W110747544 abstract "Via genetic alterations, malignant transformation and proliferation are associated with extensive alterations of mitochondrial energy metabolism of tumor cells. Thus, inhibition of the altered form of mitochondrial energy metabolism of tumor cells may be an effective therapy for cancers. This study performed translational assessment of mitochondrial dysfunction of pancreatic cancer from in vitro gene microarray and animal efficacy studies, to early clinical studies, via the novel tumor-specific anti-mitochondrial agent, CPI-613.The gene profiles of BxPC-3 human pancreatic tumor cells and non-transformed NIH-3T3 mouse fibroblast cells (negative control), after CPI-613 or sham treatment, were assessed and compared using microarray technique. The anti-cancer efficacies of CPI-613 and Gemcitabine were assessed and compared in mice with xenograft from inoculation of BxPC-3 human pancreatic tumor cells, based on the degree of tumor growth inhibition and prolongation of survival when compared to vehicle treatment. The anti-cancer activities, according to overall survival (OS), of CPI-613 alone and in combination with Gemcitabine were assessed in patients with Stage IV pancreatic cancer.Microarray studies indicated that CPI-613 down-regulated the expression of Cyclin D3, E1, E2, F, A2, B1 and CDK2 genes of BxPC-3 pancreatic cancer cells but not non-transformed NIH-3T3 mouse fibroblast cells (negative control). In mice with pancreatic carcinoma xenografts, four weekly intraperitoneal injections of either CPI-613 (25 mg/kg/administration) or Gemcitabine (50 mg/kg/administration) inhibited tumor growth and prolonged survival when compared to vehicle treatment. The degree of tumor growth inhibition was ~2×, and prolongation of survival was ~4×, greater with CPI-613 treatment than with Gemcitabine treatment. In patients with Stage IV advanced pancreatic cancer, CPI-613 at 420-1,300 mg/m(2), given twice weekly for three weeks followed by a week of rest (i.e., 3-week-on-1-week-off) as monotherapy, provided median OS of 15 months in three patients. CPI-613 at 150-320 mg/m(2) given twice weekly on the 3-week-on-1-week-off dosing schedule, coinciding with Gemcitabine (1,000 mg/m(2)) given once weekly on the 3-week-on-1-week-off dosing schedule, provided median OS of 17.8 months in four patients. These median OS values from CPI-613 monotherapy and CPI-613 + Gemcitabine treatment tend to be longer than those in patients treated with Abraxane + Gemcitabine combination or FOLFININOX (median OS ~12 months).The dysfunctional mitochondria of pancreatic cancer cells was translationable from in vitro gene alteration and animal tumor model studies to patients with advanced Stage IV pancreatic cancer, as reflected by the anti-cancer activities of the tumor-specific anti-mitochondrial agent, CPI-613, in these studies." @default.
• W110747544 created "2016-06-24" @default.
• W110747544 creator A5012080305 @default.
• W110747544 creator A5015015309 @default.
• W110747544 creator A5048492805 @default.
• W110747544 creator A5056511019 @default.
• W110747544 creator A5056773379 @default.
• W110747544 creator A5070583648 @default.
• W110747544 date "2014-09-01" @default.
• W110747544 modified "2023-09-27" @default.
• W110747544 title "Translational assessment of mitochondrial dysfunction of pancreatic cancer from in vitro gene microarray and animal efficacy studies, to early clinical studies, via the novel tumor-specific anti-mitochondrial agent, CPI-613." @default.
• W110747544 cites W1931508686 @default.
• W110747544 cites W1974922522 @default.
• W110747544 cites W1979538859 @default.
• W110747544 cites W2005021386 @default.
• W110747544 cites W2013744880 @default.
• W110747544 cites W2022784273 @default.
• W110747544 cites W2040935952 @default.
• W110747544 cites W2043565416 @default.
• W110747544 cites W2046577405 @default.
• W110747544 cites W2060033475 @default.
• W110747544 cites W2067337288 @default.
• W110747544 cites W2089756467 @default.
• W110747544 cites W2092554910 @default.
• W110747544 cites W2096160279 @default.
• W110747544 cites W2097259163 @default.
• W110747544 cites W2102322990 @default.
• W110747544 cites W2118797060 @default.
• W110747544 cites W2119638459 @default.
• W110747544 cites W2122128696 @default.
• W110747544 cites W2138155367 @default.
• W110747544 cites W2145004989 @default.
• W110747544 cites W2151253787 @default.
• W110747544 cites W2158734599 @default.
• W110747544 cites W2159370558 @default.
• W110747544 cites W2165480504 @default.
• W110747544 doi "https://doi.org/10.3978/j.issn.2305-5839.2014.05.08" @default.
• W110747544 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4205874" @default.
• W110747544 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25405166" @default.
• W110747544 hasPublicationYear "2014" @default.
• W110747544 type Work @default.
• W110747544 sameAs 110747544 @default.
• W110747544 citedByCount "13" @default.
• W110747544 countsByYear W1107475442015 @default.
• W110747544 countsByYear W1107475442019 @default.
• W110747544 countsByYear W1107475442020 @default.
• W110747544 countsByYear W1107475442021 @default.
• W110747544 countsByYear W1107475442022 @default.
• W110747544 crossrefType "journal-article" @default.
• W110747544 hasAuthorship W110747544A5012080305 @default.
• W110747544 hasAuthorship W110747544A5015015309 @default.
• W110747544 hasAuthorship W110747544A5048492805 @default.
• W110747544 hasAuthorship W110747544A5056511019 @default.
• W110747544 hasAuthorship W110747544A5056773379 @default.
• W110747544 hasAuthorship W110747544A5070583648 @default.
• W110747544 hasConcept C104317684 @default.
• W110747544 hasConcept C121608353 @default.
• W110747544 hasConcept C126322002 @default.
• W110747544 hasConcept C150194340 @default.
• W110747544 hasConcept C186836561 @default.
• W110747544 hasConcept C2780210213 @default.
• W110747544 hasConcept C2780258809 @default.
• W110747544 hasConcept C502942594 @default.
• W110747544 hasConcept C55493867 @default.
• W110747544 hasConcept C71924100 @default.
• W110747544 hasConcept C8415881 @default.
• W110747544 hasConcept C86803240 @default.
• W110747544 hasConceptScore W110747544C104317684 @default.
• W110747544 hasConceptScore W110747544C121608353 @default.
• W110747544 hasConceptScore W110747544C126322002 @default.
• W110747544 hasConceptScore W110747544C150194340 @default.
• W110747544 hasConceptScore W110747544C186836561 @default.
• W110747544 hasConceptScore W110747544C2780210213 @default.
• W110747544 hasConceptScore W110747544C2780258809 @default.
• W110747544 hasConceptScore W110747544C502942594 @default.
• W110747544 hasConceptScore W110747544C55493867 @default.
• W110747544 hasConceptScore W110747544C71924100 @default.
• W110747544 hasConceptScore W110747544C8415881 @default.
• W110747544 hasConceptScore W110747544C86803240 @default.
• W110747544 hasIssue "9" @default.
• W110747544 hasLocation W1107475441 @default.
• W110747544 hasOpenAccess W110747544 @default.
• W110747544 hasPrimaryLocation W1107475441 @default.
• W110747544 hasRelatedWork W110747544 @default.
• W110747544 hasRelatedWork W1995076802 @default.
• W110747544 hasRelatedWork W2030196256 @default.
• W110747544 hasRelatedWork W2089179463 @default.
• W110747544 hasRelatedWork W2159441446 @default.
• W110747544 hasRelatedWork W2319496893 @default.
• W110747544 hasRelatedWork W2917335837 @default.
• W110747544 hasRelatedWork W2917514204 @default.
• W110747544 hasRelatedWork W2919642485 @default.
• W110747544 hasRelatedWork W2465223688 @default.
• W110747544 hasVolume "2" @default.
• W110747544 isParatext "false" @default.
• W110747544 isRetracted "false" @default.
• W110747544 magId "110747544" @default.
• W110747544 workType "article" @default.